WVE vs. URGN, AKBA, RAPT, MRNS, ARWR, XENE, IDYA, FOLD, PTCT, and MOR
Should you be buying Wave Life Sciences stock or one of its competitors? The main competitors of Wave Life Sciences include UroGen Pharma (URGN), Akebia Therapeutics (AKBA), RAPT Therapeutics (RAPT), Marinus Pharmaceuticals (MRNS), Arrowhead Pharmaceuticals (ARWR), Xenon Pharmaceuticals (XENE), IDEAYA Biosciences (IDYA), Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT), and MorphoSys (MOR). These companies are all part of the "pharmaceutical preparations" industry.
UroGen Pharma (NASDAQ:URGN) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
UroGen Pharma received 8 more outperform votes than Wave Life Sciences when rated by MarketBeat users. Likewise, 73.29% of users gave UroGen Pharma an outperform vote while only 67.18% of users gave Wave Life Sciences an outperform vote.
Wave Life Sciences has a net margin of -54.61% compared to Wave Life Sciences' net margin of -123.74%.
UroGen Pharma has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -0.99, meaning that its share price is 199% less volatile than the S&P 500.
Wave Life Sciences has higher revenue and earnings than UroGen Pharma. Wave Life Sciences is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.
91.3% of UroGen Pharma shares are owned by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are owned by institutional investors. 11.1% of UroGen Pharma shares are owned by company insiders. Comparatively, 31.1% of Wave Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
UroGen Pharma currently has a consensus price target of $46.00, suggesting a potential upside of 245.86%. Wave Life Sciences has a consensus price target of $11.17, suggesting a potential upside of 80.69%. Given Wave Life Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe UroGen Pharma is more favorable than Wave Life Sciences.
In the previous week, Wave Life Sciences had 4 more articles in the media than UroGen Pharma. MarketBeat recorded 5 mentions for Wave Life Sciences and 1 mentions for UroGen Pharma. Wave Life Sciences' average media sentiment score of 1.87 beat UroGen Pharma's score of 1.15 indicating that UroGen Pharma is being referred to more favorably in the media.
Summary
Wave Life Sciences beats UroGen Pharma on 9 of the 17 factors compared between the two stocks.
Get Wave Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Wave Life Sciences Competitors List
Related Companies and Tools
